35 research outputs found
Gene-Drug Interaction in Stroke
Stroke is the third cause of mortality and one of most frequent causes of long-term neurological disability, as well as a complex disease that results from the interaction of environmental and genetic factors. The focus on genetics has produced a large number of studies with the objective of revealing the genetic basis of cerebrovascular diseases. Furthermore, pharmacogenetic research has investigated the relation between genetic variability and drug effectiveness/toxicity. This review will examine the implications of pharmacogenetics of stroke; data on antihypertensives, statins, antiplatelets, anticoagulants, and recombinant tissue plasminogen activator will be illustrated.
Several polymorphisms have been studied and some have been associated with positive drug-gene interaction on stroke, but the superiority of the genotype-guided approach over the clinical approach has not been proved yet; for this reason, it is not routinely recommended
Italian Revised Memory and Behavior Problems Checklist
Nella pagine seguenti sono riportate le istruzioni di somministrazione della versione Italiana della check list RMBPC di Teri et al. (1992). Le proprietà psicometriche della versione italiana sono state descritte da Ottoboni et al. (In press)
Secondary Stroke Prevention in Women
In a meta-analysis of results from 21 randomized trials comparing antiplatelet therapy with placebo in 18,270 patients with prior stroke or transient ischemic attack, antiplatelet therapy was associated with a 28% relative odds reduction in nonfatal strokes and a 16% reduction in fatal strokes, while another trial for secondary prevention with atorvastastin 80 mg showed a 16% risk reduction in time to first occurrence of stroke (adjusted hazard ratio: 0·84, 95% CI: 0·71–0·99). However, few studies have examined the sex differences regarding the efficacy of these treatments. Specifically, recent studies have reported higher rates of perioperative complications during endarterectomy in women. Nonetheless, to date, the data on the effects of carotid artery stenting in women, coming from diverse studies and meta-analyses, have been limited owing to the small number of female patients examined. Owing to this, the evidence of the benefit for women is unclear. Peculiar pathophysiological aspects of stroke, the h..
An Overview on Primary Progressive Aphasia and Its Variants
We present a review of the literature on Primary Progressive Aphasia (PPA) together with the analysis of neuropschychological and neuroradiologic profiles of 42 PPA patients. Mesulam originally defined PPA as a progressive degenerative disorder characterized by isolated language impairment for at least two years. The most common variants of PPA are: (1) Progressive nonfluent aphasia (PNFA), (2) semantic dementia (SD), (3) logopenic progressive aphasia (LPA). PNFA is characterized by labored speech, agrammatism in production, and/or comprehension. In some cases the syndrome begins with isolated deficits in speech. SD patients typically present with loss of word and object meaning and surface dyslexia. LPA patients have word-finding difficulties, syntactically simple but accurate language output and impaired sentence comprehension. The neuropsychological data demonstrated that SD patients show the most characteristic pattern of impairment, while PNFA and LPA overlap within many cognitive domains. The neuroimaging analysis showed left perisylvian region involvement. A comprehensive cognitive, neuroimaging and pathological approach is necessary to identify the clinical and pathogenetic features of different PPA variants
The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries.
The docking protein p140Cap negatively regulates tumour cell features. Its relevance on
breast cancer patient survival, as well as its ability to counteract relevant cancer signalling
pathways, are not fully understood. Here we report that in patients with ERBB2-amplified
breast cancer, a p140Cap-positive status associates with a significantly lower probability of
developing a distant event, and a clear difference in survival. p140Cap dampens ERBB2-
positive tumour cell progression, impairing tumour onset and growth in the NeuT mouse
model, and counteracting epithelial mesenchymal transition, resulting in decreased metastasis
formation. One major mechanism is the ability of p140Cap to interfere with ERBB2-
dependent activation of Rac GTPase-controlled circuitries. Our findings point to a specific role
of p140Cap in curbing the aggressiveness of ERBB2-amplified breast cancers and suggest
that, due to its ability to impinge on specific molecular pathways, p140Cap may represent a
predictive biomarker of response to targeted anti-ERBB2 therapies
Access to
Stroke is the third cause of mortality and one of most frequent causes of long-term neurological disability, as well as a complex disease that results from the interaction of environmental and genetic factors. The focus on genetics has produced a large number of studies with the objective of revealing the genetic basis of cerebrovascular diseases. Furthermore, pharmacogenetic research has investigated the relation between genetic variability and drug effectiveness/toxicity. This review will examine the implications of pharmacogenetics of stroke; data on antihypertensives, statins, antiplatelets, anticoagulants, and recombinant tissue plasminogen activator will be illustrated. Several polymorphisms have been studied and some have been associated with positive drug-gene interaction on stroke, but the superiority of the genotype-guided approach over the clinical approach has not been proved yet; for this reason, it is not routinely recommended
Can early counselling and support for Alzheimer's disease caregivers reduce burden? Study protocol for a multicenter randomized controlled trial
Background: The activity of “caregiving” for people affected with Alzheimer's disease (AD) is associated with an augmentation in
health problems (anxiety, depression, stress, increased mortality), as well as in social and financial problems. Different methods of
counselling, to reduce caregiver anxiety and depression, have been shown to be effective.
Methods/Design: This study will be a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled superiority
trial with two parallel groups. Two hundred and sixty-four caregivers of AD patients will be randomly allocated to the modified
Mittelmann psychosocial intervention or an educational intervention. The treatment will consist of 6 hours of counselling and
psychosocial support to caregivers, administered by psychologists, along with a specific telephone support service, whereas the active
control treatment will be 6 hours of general information about AD. The primary endpoint is change in caregiver burden measured
with the Zarit Burden Interview. Secondary endpoints comprise caregiver depression, anxiety and quality of life. All endpoints will be
measured at baseline, 6, 12 and 24 months post treatment.
Discussion: The results of this trial will be helpful to supply the efficacy of early counselling and psychosocial support for AD caregivers
and offer in-depth useful information for stakholders and policy makers to implement strategies for caregivers.
Trial registration: Clinical Trials.gov identifier: NCT02685787; registered on 6 February 2016.
Ethics: This trial has been approved by Umbria Ethical Review Committee, Italy and will be performed in accordance with the norms
on Good Clinical Practice and the Helsinki Declaration.
Informed consent: Written informed consent will be obtained from the caregivers